ALECTOR, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • November 16th, 2018 • Alector, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of , and is between Alector, Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”).
8,350,000 Shares ALECTOR, INC. COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • February 4th, 2020 • Alector, Inc. • Biological products, (no disgnostic substances) • New York
ALECTOR, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • November 16th, 2018 • Alector, Inc. • Biological products, (no disgnostic substances) • California
This Change in Control and Severance Agreement (the “Agreement”) is made between Alector, Inc. (the “Company”) and [NAME] (the “Executive”), effective as of [DATE] (the “Effective Date”).
10,869,566 Shares ALECTOR, INC. COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE UNDERWRITING AGREEMENT January 17, 2024Underwriting Agreement • January 19th, 2024 • Alector, Inc. • Biological products, (no disgnostic substances) • New York
CONFIDENTIAL CONSULTING AGREEMENTConfidential Consulting Agreement • November 4th, 2021 • Alector, Inc. • Biological products, (no disgnostic substances) • California
This Confidential Consulting Agreement (the “Agreement”) is executed as of the date shown on the signature page (the “Effective Date”), by and between FLG Partners, LLC, a California limited liability company (“FLG”), and the entity identified on the signature page (“Client”).
January 26, 2019 Calvin Yu c/o Alector, Inc. South San Francisco, CA 94080 Re: Confirmatory Employment Letter Dear Calvin:Letter Agreement • January 29th, 2019 • Alector, Inc. • Biological products, (no disgnostic substances)
This letter agreement (the “Agreement”) is entered into between Calvin Yu (“you”) and Alector, Inc. (the “Company” or “we”), effective as of January 25, 2019 (the “Effective Date”), to confirm the terms and conditions of your employment with the Company as of the Effective Date. This Agreement supersedes and replaces any and all employment terms, compensation, or benefits you may have had or to which you may have been entitled prior to the Effective Date.
SUMMARY OF BASIC LEASE INFORMATIONLease • January 7th, 2019 • Alector, Inc. • Biological products, (no disgnostic substances) • California
ALECTOR, INC. COMMON STOCK SALES AGREEMENTSales Agreement • November 7th, 2023 • Alector, Inc. • Biological products, (no disgnostic substances) • New York
SUBLEASESublease • January 7th, 2019 • Alector, Inc. • Biological products, (no disgnostic substances) • California
This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between HCP OYSTER POINT III LLC, a Delaware limited liability company (“Landlord”), and CYTOMX THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE...Development and Option Agreement • January 7th, 2019 • Alector, Inc. • Biological products, (no disgnostic substances) • Delaware
This Co-Development and Option Agreement (this “Agreement”) is made and entered into effective as of October 16, 2017 (the “Execution Date”) by and between Alector, Inc. (f/k/a Alector LLC), a Delaware corporation (“Licensor”), and AbbVie Biotechnology, Ltd., a Bermuda limited company (“AbbVie”). Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ALECTOR, INC. AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT April 26, 2018Registration Rights Agreement • January 7th, 2019 • Alector, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (“Agreement”) is made as of April 26, 2018, by and among Alector, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder”. Capitalized terms used herein without definition shall, unless otherwise indicated, have the meaning specified in the Company’s Certificate of Incorporation, as may be amended or restated from time to time.
ALECTOR, INC. COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • May 13th, 2020 • Alector, Inc. • Biological products, (no disgnostic substances) • New York
Set forth below are guidelines for use by the Company and the Managers in connection with the Managers’ continuous due diligence efforts in connection with the sale and distribution of the Shares pursuant to the Agreement. For the avoidance of doubt, the Company has agreed that no sales under the Agreement will be requested or made at any time the Company is, or could be deemed to be, in possession of material non-public information with respect to the Company.
SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE...Collaboration Agreement • October 12th, 2018 • Alector, Inc. • Biological products, (no disgnostic substances) • New York
*** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request.
ContractCollaboration and License Agreement • August 3rd, 2021 • Alector, Inc. • Biological products, (no disgnostic substances) • New York
*** Certain information has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
AMENDMENT NUMBER ONE to the2019 Collaboration Agreement • February 28th, 2023 • Alector, Inc. • Biological products, (no disgnostic substances)
This Amendment Number One (this “Amendment”), effective as of August 16, 2022 (the “Amendment Effective Date”), amends the 2019 Collaboration Agreement (the “Agreement”) dated August 16, 2019, by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and Alector LLC, a Delaware limited liability company having an address at 131 Oyster Point Blvd., Suite 600, San Francisco, CA 94080 (hereinafter “Alector”). Capitalized terms used herein and not defined shall have the meanings ascribed to them in the Agreement.
SEPARATION AGREEMENT AND RELEASE OF CLAIMSSeparation Agreement And • January 3rd, 2022 • Alector, Inc. • Biological products, (no disgnostic substances) • California
This Separation Agreement and Release of Claims (the “Separation Agreement”) is entered into by and between Alector, LLC (“Alector” or the “Company”) and Shehnaaz Suliman (“you” or “your”). The term “Party” or “Parties” as used herein shall refer to you, the Company, or both, as may be appropriate.
AMENDMENT NO. 1 TO CO-DEVELOPMENT AND OPTION AGREEMENTDevelopment and Option Agreement • May 4th, 2023 • Alector, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (this “Amendment”) is effective as of February 13, 2023 (the “Amendment Effective Date”) by and between Alector, Inc., a Delaware corporation (“Licensor”), and AbbVie Biotechnology Ltd. (“AbbVie”). Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
TRANSITION AGREEMENTTransition Agreement • September 7th, 2021 • Alector, Inc. • Biological products, (no disgnostic substances) • California
This Transition Agreement (the “Transition Agreement”) is entered into by and between Alector, LLC (“Alector” or the “Company”) and Shehnaaz Suliman (“you” or “your”). The term “Party” or “Parties” as used herein shall refer to you, the Company, or both, as may be appropriate.
Certain information has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.2019 Collaboration Agreement • November 12th, 2019 • Alector, Inc. • Biological products, (no disgnostic substances)
THIS 2019 COLLABORATION AGREEMENT (the “Agreement”) is made effective as of August 16, 2019 (the “Effective Date”), by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and ALECTOR LLC., a Delaware limited liability company having an address at 131 Oyster Point Blvd., Suite 600, San Francisco, CA 94080 and its Affiliates (“Alector”).
